

# Lawsuits against the Brazilian Unified Health System regarding Bladder/Ureteral Cancer

Fernando Korkes<sup>1,2,3</sup> Mariana Avelar da Silveira<sup>1</sup> Flavio Tocci<sup>1</sup> Carlos Pedrotti<sup>1</sup>  
Vanessa Damazio Teich<sup>1</sup> Luciana Holz Camargo de-Barros<sup>3</sup> Sidney Glinas<sup>1,2</sup>

<sup>1</sup>Research Department, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

<sup>2</sup>Research Department, Centro Universitário FMABC, Santo André, SP, Brazil

<sup>3</sup>Instituto Oncoguia, São Paulo, SP, Brazil

**Address for correspondence** Mariana Avelar da Silveira, Departamento de Pesquisa, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil (e-mail: mariana.avelardasilveira@gmail.com).

Braz J Oncol 2024;20:s00441787970.

## Abstract

**Objective** To evaluate the technical notes (TNs) issued by the Center for Technical Support of the Judiciary (Núcleo de Apoio Técnico do Poder Judiciário, NAT-Jus, in Portuguese) of the Brazilian Ministry of Justice regarding lawsuits against the Brazilian Unified Health System (Sistema Único de Saúde, SUS, in Portuguese) concerning bladder/ureteral cancer, in order to better advise the formulation of public policies regarding oncologic care.

**Materials and Methods** A cross-sectional study on the TNs issued by NAT-Jus regarding lawsuits from patients against SUS from 2019 to 2023 concerning bladder or ureteral cancer.

**Results** A total of 137 TNs were issued. Most plaintiffs were male patients (70.8%), with a mean age of  $69.1 \pm 17.6$  years. The lawsuits were filed in an attempt to obtain medications (67%), medical care or procedures (26%), or other health products (7%). The most common medications requested were immuno-oncology (IO) therapeutic agents, in 66 cases (pembrolizumab, avelumab, nivolumab, and atezolizumab), followed by the Bacillus Calmette-Guerin (BCG) vaccine ( $n = 13$ ), chemotherapeutic agents in 5 cases, erdafitinib in 2 cases, and enfortumab vedotin in 1 case.

Pembrolizumab was the medication most frequently requested by patients undergoing treatment for bladder or ureteral cancer. Out of more than 50 thousand TNs, there were 1,349 requests for this medication. Bladder or ureteral cancer was responsible for 3.4% of all the demands for pembrolizumab.

It is also notable that lawsuits were more common in the Southern ( $n = 47$ ), followed by the Southeastern ( $n = 26$ ), Northeastern ( $n = 20$ ), and Midwestern ( $n = 6$ ) regions. The lawsuits in the South were more often related to expensive medications. In the Northeast and Midwest, there were proportionally more lawsuits demanding medical procedures. The Brazilian Federal Government lost the lawsuits, representing expenses of BRL 42.1 million with these novel medications within the period evaluated.

## Keywords

- ▶ ureteral neoplasms
- ▶ judicial role
- ▶ Brazil
- ▶ urinary bladder neoplasms

received  
April 9, 2024  
accepted  
May 22, 2024

DOI <https://doi.org/10.1055/s-0044-1787970>.  
ISSN 2526-8732.

© 2024. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (<https://creativecommons.org/licenses/by/4.0/>).

Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

**Conclusion** Bladder cancer treatment within SUS faces obstacles and shortages of essential medications. Moreover, advanced and costly therapies are not widely available, straining the public healthcare system and resulting in increasing legal costs. Collaboration among the government, the scientific community, and patient advocacy organizations is crucial to ensure the sustainability of SUS in the face of these challenges.

## Introduction

The Brazilian Constitution grants the right to universal health to all Brazilian citizens. In such context, the Brazilian Unified Health System (Sistema Único de Saúde, SUS, in Portuguese) aims to provide universal health coverage within the country. Pharmaceutical care is also granted, even though there are huge challenges to properly attain these civil rights. It is widely known that the success of oncological treatment is primarily determined by early diagnosis and adequate treatment. This is even more important for time-sensitive diseases, such as bladder cancer. Even though SUS is universal in Brazil, it is not always efficient, and there are situations in which the users seek legal aid aiming to obtain the desired access to health treatments.<sup>1</sup> Petitioning for medications via the judiciary system represents a mean to obtain legal right, and it is also a measure that influences national drug policy. The concept of essential drugs in SUS has led to the creation of the National List of Essential Medications (Relação Nacional de Medicamentos Essenciais, RENAME, in Portuguese) to universalize the availability of drugs according to growing demands. However, drugs not approved by the National Committee of Incorporation of New Technologies into SUS (Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde, CONITEC, in Portuguese) are not mentioned in RENAME. These drugs are generally requested by the patients through lawsuits against SUS.

To aid in these lawsuits, the Center for Technical Support of the Judiciary (Núcleo de Apoio Técnico do Poder Judiciário, NAT-Jus, in Portuguese) was created. It integrates the judiciary system with relevant health institutions, aiming to help the judges in scientific matters. Since 2019, it has released over 50 thousand technical notes (TNs) based on individual lawsuits (77% regarding medications, 18%, procedures, and 5%, health products).<sup>2</sup> These TNs are scientific documents formulated by technicians from the supporting staff of the Judiciary system, and they aim to answer specific questions about the potential benefits of a technology for a clinical condition in an individual case.

Currently, there are several challenges in SUS for patients treated for bladder cancer. Waiting times in most public hospitals are long.<sup>3,4</sup> For non-muscle-invasive bladder cancer (NMIBC), cystoscopies and surgeries are often required, as well as adjunctive treatments. There have been shortages of the Bacillus Calmette-Guerin (BCG) vaccine, the first-line treatment for NMIBC. Topical chemotherapies, the second option

for NMIBC, are not widely available.<sup>5</sup> Robotic surgery has also demonstrated benefits for radical cystectomy in muscle-invasive bladder cancer (MIBC), but it is not available in most public hospitals.<sup>6</sup> Additionally, there have been great advances in the treatment of metastatic disease. Several immuno-oncology (IO) therapeutic agents have demonstrated benefits in terms of improving survival.<sup>7-9</sup> Antibody-drug conjugates (ADCs) and targeted therapies (TTs) have also been included in the armamentarium of bladder cancer treatment throughout the world and in the private setting in Brazil.<sup>10-12</sup> However, in the public setting, these treatments are not granted, and patients can only be treated with chemotherapy.

These treatments have increased patient survival in the metastatic setting, but they have also increased the costs.<sup>13</sup> The prices of these new drugs are much higher than those of the usual chemotherapeutic agents and, since most patients in the public setting cannot pay for these expanses, they resort to the judiciary system for help.<sup>13</sup> The proper knowledge of the reality of the treatment of bladder cancer is important for many reasons, but mainly to help plan public health policies. This is even more important given the high monetary burden of the treatment of patients with bladder cancer.<sup>14</sup>

The present study aimed to evaluate lawsuits against SUS to obtain better treatment for patients with bladder/ureteral cancer.

## Materials and Methods

We conducted a cross-sectional study to evaluate the TNs issued by NAT-Jus regarding lawsuits filed by patients against SUS from 2019 to 2023, concerning bladder or ureteral cancer (International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] codes C66 or C67). Maps were created on the MapChart website (mapchart.net). The prices of the medications were based on the list by the Chamber for the Regulation of the Medication Market (Câmara de Regulação do Mercado de Medicamentos, CMED, in Portuguese) of the Brazilian Ministry of Health, considering 18% of tax.<sup>15</sup> A USD /BRL rate of US\$ 1/R\$ 4.92 was considered for conversion within the manuscript.

Approval of the Institutional Review Board was not required for the present study, as only anonymous public data was used, according to article 2 of Resolution no. 510/2016 of the Brazilian National Health Council (Conselho Nacional de Saúde, CNS, in Portuguese).

**Table 1** Requests in 137 technical notes evaluated and their outcome

Request	Technical note	Favorable	
Surgical procedure	20	75.0%	(15)
<i>Cystoscopy</i>	4	100.0%	(4)
<i>Transurethral resection of bladder tumor</i>	9	88.9%	(8)
<i>Major surgical procedure</i>	7	42.8%	(3)
Specialist consultation	7	100.0%	(7)
Hospital admission	2	50.0%	(1)
Home care	2	50.0%	(1)
Exams	3	0	(0)
Materials	4	100.0%	(4)
Medications	87	71.3%	(62)

## Results

A total of 137 TNs were issued for lawsuits filed by patients being treated for bladder/ureteral cancer. Most plaintiffs were male patients (70.8%), with a mean age of 69.1 ± 17.6 (range: 21–92) years; 129 cases were associated with bladder cancer, and 8, with ureteral cancer.

The lawsuits had been filed with the intent to obtain medications (67%), medical care or procedures (26%), or other health products (7%) (► **Table 1**). The most common medications requested were IO therapeutic agents, in 66 cases (pembrolizumab, avelumab, nivolumab, and atezolizumab), followed by BCG, in 13 cases, chemotherapeutic agents, in 5 cases (gemcitabine, docetaxel, and vinflunine), TTs, in 2 cases (erdafitinib), and ADCs, in 1 case (enfortumab vedotin) (► **Table 2**). For patients with ureteral cancer, 75% of the lawsuits involved the medication pembrolizumab. Almost all TNs granted these medications for an unlimited amount of time; time was only predefined in 6 TNs (6 months in 2, 1 year in 2, and 2 years in 2 cases).

Pembrolizumab was the medication most often requested by patients undergoing treatment for bladder or ureteral

cancer, with 1,349 requests out of more than 50 thousand TNs. Bladder or ureteral cancer was responsible for 3.4% of all of the requests for pembrolizumab. Erdafitinib was the reason for 2 additional TNs, registered under code C64 (kidney cancer), and related to renal pelvis tumors with fibroblast growth factor (FGFR) mutations.


The distribution of the lawsuits in terms of the Brazilian states and cities is outlined in ► **Map 1**. Lawsuits were more common in the Southern (n = 47), followed by the South-eastern (n = 26), Northeastern (n = 20), and Midwestern (n = 6) regions; no lawsuits were filed in the Northern region. The lawsuits in the South were more often related to expensive medications. In the Northeast and Midwest, there were proportionally more lawsuits demanding medical procedures (► **Fig. 1**).

The costs of some of the medications involved in the lawsuits are demonstrated in ► **Table 3**, according to the CMED. Lawsuits demanding IO therapeutic agents, TTs, or ADCs for patients with bladder cancer aimed at obtaining BRL 58.4 million. The Brazilian Federal Government lost the causes, representing BRL 42.1 million in expenses with these medications within the period evaluated.

**Table 2** Number of lawsuits demanding drugs and their current approval and recommendations

	Lawsuits	Favorable		ANVISA approval	CONITEC approval	NCCN guidelines
Pembrolizumab	46	69.6%	(32)	Yes	–	Yes
Avelumab	13	76.9%	(10)	Yes	–	Yes
Atezolizumab	5	40.0%	(2)	Yes	–	Yes
Nivolumab	1	100%	(1)	Yes	–	Yes
Erdafitinib	2	100%	(2)	Yes	–	Yes
Enfortumab vedotin	1	100%	(1)	Yes	–	Yes
BCG vaccine	13	92.3%	(12)	Yes	Yes	Yes
Chemotherapy	5	40.0%	(2)	Yes	Yes	Yes

Abbreviations: ANVISA, Agência Nacional de Vigilância Sanitária (Brazilian Health Regulatory Agency); BCG, Bacillus Calmette-Guerin; CONITEC, Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde (National Committee of Incorporation of New Technologies into the Brazilian Unified Health System); NCCN, United States National Comprehensive Care Network.



Map 1 Distribution of lawsuits filed by patients with bladder or ureteral cancer according to Brazilian state.




Fig. 1 Distribution of lawsuits according to reason in each Brazilian region. Abbreviations: N, North; NE, Northeast; MW, Midwest; SE, Southeast; S, South.

## Discussion

The incidence and prevalence of bladder cancer is increasing in Brazil.<sup>16</sup> Fortunately, new technologies are helping to improve cure and survival rates. However, these improvements come at high costs, and they are adding a substantial economic burden to the health system.<sup>13,14</sup>

The SUS is a universal health system, and health care is a constitutional legal right in Brazil. The three branches of power of the Brazilian government work to balance these rights. Whereas the Executive branch manages SUS, the Judicial branch can be assessed by anyone who believes that their rights are not fully granted.

Even though Brazil is one of the few countries that recognizes health as a legal right, SUS faces serious challenges, such as underfunding, improper distribution of health services throughout the country, population aging, lack of precise information, etc.

Access to medications has been one of the most common demands in Brazilian courts in lawsuits filed by oncological patients. These lawsuits are normally associated with a high

**Table 3** Costs of medications according to the CMED list<sup>15</sup>

Drug	Commercial name in Brazil	Manufacturer	Presentation	Price in BRL (no tax)	Price in BRL (+ 18% in tax)	Estimated cost/year (in BRL)
<b>Erdafitinib</b>	<b>(oral)</b>					<b>753,563.04</b>
Erdafitinib	Erfandel	Janssen	3 mg X 84	33,557.67	47,097.68	
Erdafitinib	Erfandel	Janssen	3 mg X 56	50,336.53	70,646.54	
Erdafitinib	Erfandel	Janssen	4 mg X14	11,185.89	15,699.23	
Erdafitinib	Erfandel	Janssen	4 mg X28	22,371.79	31,398.46	
Erdafitinib	Erfandel	Janssen	4 mg X56	44,743.57	62,796.91	
Erdafitinib	Erfandel	Janssen	5 mg X28	27,964.74	39,248.08	
<b>Pembrolizumab</b>						<b>312,608.32</b>
Pembrolizumab	Keytruda	Merck Sharp & Dome	100 mg/mL (4mL)	13,921.08	19,538.02	
<b>Avelumab</b>	<b>(intravenous)</b>					<b>719,974.08</b>
Avelumab	Bavencio	Merck S/A	20 mg/mL (10 mL)	5,343.65	7,499.73	
<b>Atezolizumab</b>	<b>(intravenous)</b>					<b>525,102.40</b>
Atezolizumab	Tecentriq	Roche	1200 mg (20 mL)	23,383.87	32,818.90	
Atezolizumab	Tecentriq	Roche	840 mg (14 mL)	16,368.71	22,973.23	
<b>Enfortumab vedotin</b>	<b>(intravenous)</b>					<b>1,103,811.72</b>
Enfortumab vedotin	Padcev	Adium	20 mg	4,853.72	6,812.12	
Enfortumab vedotin	Padcev	Adium	30 mg	7,282.65	10,221.09	
<b>Nivolumab</b>	<b>(intravenous)</b>					<b>208,405.44</b>
Nivolumab	Opdivo	Bristol-Myers Squibb	40 mg/mL (4 mL)	3,093.57	4,341.78	
Nivolumab	Opdivo	Bristol-Myers Squibb	100 mg/mL (10 mL)	7,733.91	10,854.42	
<b>BCG</b>	<b>(intravesical)</b>					<b>18,768.33</b>
Mycobacterium bovis	Imuno BCG	Fundação Ataulpho de Paiva	40 mg (1 unit)	356.59	-	
Mycobacterium bovis	Imuno BCG	Fundação Ataulpho de Paiva	40 mg (2 units)	713.20	-	
Mycobacterium bovis	Urohipe	Uno Healthcare	40 mg (1 unit)	318.38	446.85	
Mycobacterium bovis	Urohipe	Uno Healthcare	40 mg (2 units)	636.79	893.73	
<b>Gemcitabine</b>	<b>(intravesical)</b>					<b>28,965.62</b>
Gemcitabine	GCIB	Cristália	1 g	1,051.84	1,282.73	
Gemcitabine	Gemzar	Eli Lilly BR	1 g	1,074.74	1,310.66	
Gemcitabine	Gemcitabine	Accord	1 g	698.58	851.93	
Gemcitabine	Gemcitabine	Zyodus Nikkho	1 g	698.58	851.93	
Gemcitabine	HETGEM	Camber	1 g	603.20	735.61	
Gemcitabine	Gemcitabine	Farma Vision	1 g	603.20	735.61	
<b>Vinflunine</b>	<b>(intravenous)</b>					<b>188,096.00</b>
Vinflunine	Javlor	Pierre Fabre	25 mg/mL (2 mL)	602.39	845.45	
Vinflunine	Javlor	Pierre Fabre	25 mg/mL (10mL)	2939.12	4125.02	

Abbreviations: BCG, Bacillus Calmette-Guerin; CMED, Câmara de Regulação do Mercado de Medicamentos (Chamber for the Regulation of the Medication Market).

economic burden, and they must be evaluated with caution. There are specific criteria that are recommended in this judicial decision process: a technical analysis; medication registry in the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, ANVISA, in Portuguese); clinical guidelines; incorporation of the medication into SUS (after CONITEC approval); inclusion of the medication in specific documents such as the Health Ministry's Diagnostic and Therapeutic Guidelines (Diretrizes Diagnósticas e Terapêuticas, DDT, in Portuguese) or the Clinical Protocols and Therapeutic Guidelines (Protocolos Clínicos e Diretrizes Terapêuticas PCDT, in Portuguese), which guide cancer treatments in SUS.

Bladder cancer is already known to be an expensive disease.<sup>14,17</sup> The increasing number of cases in the last decade in Brazil,<sup>16</sup> along with the increment in costs with new drugs, bring huge concerns to the economic viability of the system.

The analysis of the lawsuits demonstrates contrasting realities. Whereas some patients are demanding relatively inexpensive treatments that should be promptly granted, others are demanding new and expensive technologies. Overall, the TNs were favorable in 72.3% of the lawsuits involving bladder/ureteral cancer. This rate is very similar to the ones previously reported in a study<sup>18</sup> evaluating 6,112 lawsuits in the state of Minas Gerais, in which 82.5% of the lawsuits had the injunctions granted, and 77.5%, in the case of genitourinary disorders.

There were 20 lawsuits demanding the right to surgical procedures: 4 of them were demanding cystoscopies and 9, transurethral resections of bladder tumors (TURBTs). These are essential procedures when treating a patient with bladder cancer, and they are already granted by law. The TNs were favorable in all of these cases, except one. More than 63% of these cases occurred in the Northeastern and Midwestern regions, which present lower Human Development Index (HDI) and less access to health services.

In two cases, patients required access to robotic and minimally-invasive technology to perform surgery, and an unfavorable recommendation was given in both cases. Additionally, there were 7 lawsuits demanding a specialist consultation (all came out favorable), 2 demanding hospital admission (50% favorable) and 2 demanding home-care treatment (50% favorable). Day-use materials such as diapers and catheters were demanded by 4 patients (100% favorable). In 3 cases, exams (positron-emission tomography [PET] scan) were required (100% unfavorable).

Lawsuits demanding medications were the most common, and some demanded access to basic treatments. In 12 cases, simple medications such as analgesics or nutritional supplements were the main issue (75% favorable). In 13 cases, the BCG vaccine was requested (92.3% favorable), and in 5, chemotherapeutic agents were requested (40% favorable).

However, most lawsuits requested access to expensive medications. The most requested drug was pembrolizumab ( $n=66$ ; 69.6% favorable), followed by avelumab ( $n=13$ ; 76.9% favorable), atezolizumab ( $n=5$ ; 50% favorable), erdafitinib ( $n=2$ ; 100% favorable), and enfortumab vedotin ( $n=1$ ; 100% favorable). Of the total, 56% of the requests

for these expensive medications occurred in the Southern region, which is known to present a higher HDI and better access to health services.

The BCG vaccine and chemotherapeutic agents are recommended by guidelines, and they have been approved by ANVISA and CONITEC. Immunotherapeutic drugs, enfortumab vedotin, and erdafitinib are also recommended by guidelines and approved by ANVISA. However, these expensive drugs were not incorporated into SUS by CONITEC.

The CONITEC is the institution that evaluates the efficacy and safety of medications, and it also provides the Ministry of Health with a cost-effectiveness point of view. Recently, the concept of cost-effectiveness thresholds has been debated.<sup>19</sup> The CONITEC has established a threshold for treatment cost of three times the per-capita gross domestic product (GDP).<sup>20</sup> In the material that we have analyzed, financial values were not available. However, an estimated cost of pembrolizumab of BRL 312,608.32/year (USD 63,538.02/year) is much higher than thrice the per-capita GDP, as recommended by the CONITEC as a threshold.<sup>21</sup> The Brazilian per-capita GDP is currently of BRL 48,829 (USD 7,507.00).

The TNs for lawsuits demanding IO therapeutic agents, TTs, or ADCs (IO + TT + ADC) for patients with bladder cancer aimed at obtaining BRL 58.4 million in the studied period. The Brazilian Federal Government lost the causes, representing BRL 42.1 million in expenses with IO + TT + ADC medications within the period evaluated.<sup>22</sup>

In the period evaluated (2019–2023), 88 thousand TNs were issued,<sup>23</sup> and approximately 965 thousand lawsuits were filed against SUS.<sup>24</sup> Therefore, these TNs represent a sample of around 9.1% of the lawsuits filed against SUS, with an estimated expense of BRL 458.89 million. The total judicialization expenses in SUS have increased from BRL 70 million in 2008, BRL 845 million in 2014, to around BRL 2 billion in 2022.<sup>25,26</sup>

Federal expenditures with public health in Brazil were of approximately BRL 115.3 billion/year in the last years. There is an estimated deficit of BRL 21.7 billion each year. There are currently 520 thousand lawsuits regarding health issues. Over 50% of them are related to medications, and more than 90% are associated with medications not currently offered by SUS.<sup>22</sup> These demands have increased exponentially in the last decade. If this issue is not properly addressed, SUS will soon become unsustainable.

For bladder cancer, these lawsuits might skyrocket in the next few years. Immunotherapy is now used for NMIBC, MIBC, and metastatic bladder cancer. However, in the last year, a new combination of treatments has more than doubled the overall survival of patients with bladder cancer, an outcome rarely seen in oncologic drug development. It has been granted United States Food and Drug Administration (FDA) approval and caused a change in the guidelines of the United States National Comprehensive Care Network (NCCN) as a new first-line treatment for metastatic bladder cancer.<sup>27</sup> It significantly improves survival and increases the cost by combining two expensive medications, enfortumab vedotin and pembrolizumab.<sup>27</sup> In the period herein evaluated, there was only one TN demanding enfortumab Vedotin. But, as it

has happened with pembrolizumab, it is expected that demands significantly increase within the next years.

Currently, patients in Brazil with metastatic bladder cancer are mostly treated with chemotherapy regimens such as gemcitabine-cisplatin, gemcitabine-carboplatin, and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), with a total expenditure of treatment (6 cycles) ranging from BRL 30 thousand to BRL 50 thousand. However, the current NCCN guidelines recommend three main regimens as first-line options for patients with metastatic bladder cancer: chemotherapy followed by switch maintenance with avelumab; pembrolizumab; or the combination of pembrolizumab and enfortumab vedotin. These treatments would represent expenditures of BRL 769,974.08/year (chemotherapy + avelumab), BRL 312,608.32/year (pembrolizumab), and BRL 1,085,276.52/year (pembrolizumab + enfortumab vedotin). Therefore, not only prices might dramatically increase, but also, instead of a 3-month course of chemotherapy, patients in the new regimens will receive lifelong treatments.

If a rational and cautious evaluation of the incorporation of new technology into SUS is not adopted, the system will soon collapse. In such a context, further studies and collaborations between the government, the scientific community, the judiciary system, and patient advocacy organizations are extremely necessary and should be encouraged. New technologies are extremely beneficial for the medical practice; therefore, the Brazilian government has to face this reality and properly address viable solutions.

The Brazilian Constitution guarantees the right to universal healthcare for all citizens through SUS. However, there are significant challenges in realizing these rights, with patients resorting to the judicial system to access treatments. Bladder cancer treatment within SUS faces obstacles such as long queues and shortages of essential medications. Moreover, advanced and costly therapies are not widely available, straining SUS and resulting in increasing legal costs. Collaboration between the government, the scientific community, and patient advocacy organizations is crucial to ensure the sustainability of SUS in the face of these challenges.

#### Author's Contribution

FK: conception and design, data analysis and interpretation, final approval of the manuscript, and writing of the manuscript; MAS: collection and assembly of data and data analysis and interpretation; FT: collection and assembly of data and conception and design; and CP, VDT, LHCB, and SG: conception and design.

#### Conflict of Interests

The authors have no conflict of interests to declare.

#### References

- Vidal TJ, Moraes EL, Retto MPF, Silva MJSD. Demandas judiciais por medicamentos antineoplásicos: a ponta de um iceberg? *Cien Saude Colet* 2017;22(08):2539–2548. <https://www.scielo.br/j/csc/a/6JtXgc6w4TTg57ZCGptCLCS/?lang=pt> cited 2023 Dec 2
- Judiciário vai avaliar impacto das notas técnicas de saúde nas decisões judiciais\* – Portal TRF2 [Internet]. [cited 2023 Dec 2]. Available from: <https://www10.trf2.jus.br/portal/judiciario-vai-avaliar-impacto-das-notas-tecnicas-de-saude-nas-decisoes-judiciais/>
- Korkes F, Timóteo F, Martins S, et al. Dramatic Impact of Centralization and a Multidisciplinary Bladder Cancer Program in Reducing Mortality: The CABEM Project. *JCO Glob Oncol* 2021;7(07):1547–1555. <https://pubmed.ncbi.nlm.nih.gov/34767463/> cited 2023 Dec 2
- Korkes F, Palou J. High mortality rates after radical cystectomy: we must have acceptable protocols and consider the rationale of cutaneous ureterostomy for high-risk patients. *Int Braz J Urol* 2019;45(06):1090–1093
- Korkes F, Timóteo F, Ferrari KL, Reis LO. Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer. *Int Braz J Urol* 2021;47(02):232–236. <https://pubmed.ncbi.nlm.nih.gov/33284531/> cited 2023 Dec 2
- Catto JWF, Khetrapal P, Ricciardi F, et al; iROC Study Team. Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial. *JAMA* 2022;327(21):2092–2103. <https://pubmed.ncbi.nlm.nih.gov/35569079/> cited 2023 Dec 2
- Powles T, Park SH, Voog E, et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. *J Clin Oncol* 2020;38(18\_suppl):LBA1–LBA1
- Powles T, Park SH, Caserta C, et al. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. *J Clin Oncol* 2023;41(19):3486–3492. <https://pubmed.ncbi.nlm.nih.gov/37071838/> cited 2023 Dec 2
- Suzman DL, Agrawal S, Ning YM, et al. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. *Oncologist* 2019;24(04):563–569
- Loriot Y, Matsubara N, Park SH, et al; THOR Cohort 1 Investigators. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med* 2023;389(21):1961–1971. <https://pubmed.ncbi.nlm.nih.gov/37870920/> cited 2023 Dec 2
- Loriot Y, Necchi A, Park SH, et al; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med* 2019;381(04):338–348. <https://pubmed.ncbi.nlm.nih.gov/31340094/> cited 2020 Dec 22
- Approves Padcev FDA. (Enfortumab vedotin-ejfv) for Bladder Cancer [Internet]. [cited 2020 Jul 1]. Available from: <https://www.cancer.org/latest-news/fda-approves-padcev-enfortumab-vedotin-ejfv-for-bladder-cancer.html>
- Korkes F, Maluf F. Increasing costs from bladder cancer in the Brazilian Health System: the role of establishing public health policies. *Int Braz J Urol* 2021;47(02):443–447
- Korkes F, Timóteo F, Soledade LCB, et al. Stage-Related Cost of Treatment of Bladder Cancer in Brazil. *PharmacoEcon Open* 2022;6(03):461–468
- Capa CMED—Agência Nacional de Vigilância Sanitária - Anvisa [Internet]. [cited 2023 Dec 3]. Available from: <https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/cmcd>
- Timoteo F, Korkes F, Baccaglini W, Glina S. Bladder cancer trends and mortality in the Brazilian public health system. *Int Braz J Urol* 2020;46(02):224–233 <https://pubmed.ncbi.nlm.nih.gov/32022511/> cited 2023 Dec 2
- Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? *World J Urol* 2009;27(03):295–300 Available from: [/pmc/articles/PMC2694315/?report=abstract](http://pmc/articles/PMC2694315/?report=abstract)

- 18 Coelho TL, Ferré F, Campos Neto OH, Acurcio Fde A, Cherchiglia ML, Andrade EIG. Legal and health variations in drug litigation injunctions granted in Minas Gerais. *Rev Saude Publica* 2014;48(05):808–816. <https://www.scielo.br/j/rsp/a/dqCy4ZjSB7CTfFB9KPDxhmt/?lang=en> cited 2023 Dec 5
- 19 Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. *Lancet Glob Health* 2023;11(06):e833–e842. [www.thelancet.com/lancetgh](http://www.thelancet.com/lancetgh) cited 2023 Dec 2
- 20 Conitec aprova proposta de uso de limiares de custo-efetividade (LCE) nas decisões em saúde—Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde - CONITEC [Internet]. [cited 2023 Dec 2]. Available from: <https://www.gov.br/conitec/pt-br/assuntos/noticias/2022/setembro/conitec-aprova-proposta-de-uso-de-limiares-de-custo-efetividade-lce-nas-decisoes-em-saude>
- 21 Lista de Alto Risco da Administração Pública [Internet]. [cited 2023 Dec 2]. Available from: [https://sites.tcu.gov.br/listadealtorisco/sistema\\_unico\\_de\\_saude\\_acesso\\_e\\_sustentabilidade.html](https://sites.tcu.gov.br/listadealtorisco/sistema_unico_de_saude_acesso_e_sustentabilidade.html)
- 22 Impactos da judicialização da saúde são debatidos no I Congresso do Fonajus - Portal CNJ [Internet]. [cited 2023 Dec 2]. Available from: <https://www.cnj.jus.br/impactos-da-judicializacao-da-saude-sao-debatidos-no-i-congresso-do-fonajus/>
- 23 Juízes e juízas podem acessar notas técnicas sobre saúde - EjeF [Internet]. [cited 2023 Dec 5]. Available from: <https://ejef.tjmg.jus.br/e-natjus-disponibiliza-novas-funcionalidades/>
- 24 Justiça leva em média um ano para dar resposta a processos de saúde | Agência Brasil [Internet]. [cited 2023 Dec 5]. Available from: <https://agenciabrasil.ebc.com.br/saude/noticia/2023-05/justi%C3%A7a-leva-em-m%C3%A9dia-um-ano-para-dar-resposta-a-processos-de-sa%C3%BAde>
- 25 CNJ promove evento para debater as demandas da saúde no Judiciário [Internet]. [cited 2023 Dec 5]. Available from: <https://www.conjur.com.br/2022-nov-17/cnj-promove-evento-debater-demandas-saude-judiciario/>
- 26 TCU e Estados apontam aumento dos gastos com a judicialização da saúde - Portal CNJ [Internet]. [cited 2023 Dec 5]. Available from: <https://www.cnj.jus.br/tcu-e-estados-apontam-aumento-dos-gastos-com-a-judicializacao-da-saude/>
- 27 Powles TB, Perez Valderrama B, Gupta S, et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). *Ann Oncol* 2023;34:S1340 Available from <http://www.annalsofoncology.org/article/S0923753423042709/fulltext> cited 2023 Dec 2